Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab for HTLV-Associated ATLL
NCT02631746Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2017
- Primary completion
- Mar 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in adult T-cell leukemia-lymphoma (ATLL), sponsored by National Cancer Institute. Started Feb 2017; status: completed.
02
Drugs
03
Conditions
adult T-cell leukemia-lymphoma (ATLL)
Beyond the preview
Go deeper on NCT02631746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02631746.